Aclaris Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Wayne PA United States (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2013
NCT02669862
First Marketed Drug
2017
oxymetazoline (ocuclear)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ACLARIS | Aclaris Therapeutics | Aclaris Therapeutics, Inc. | Alacris

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alopecia (Phase 2)

Alopecia Areata (Phase 2)

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Cryopyrin-Associated Periodic Syndromes (Phase 2)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Keratosis (Phase 4)

Keratosis, Actinic (Phase 4)

Keratosis, Seborrheic (Phase 4)

Skin Diseases (Phase 2)

Skin Diseases, Papulosquamous (Phase 2)

Syndrome (Phase 2)

Vitiligo (Phase 2)

Warts (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 32
  • # of Trial APIs: 18